{"id":175534,"name":"MAYO CLINIC","slug":"mayo-clinic","state":"DC","description":"Government affairs firm","totalSpending":1180000,"filings":24,"yearlySpending":[{"year":2018,"income":180000},{"year":2019,"income":180000},{"year":2020,"income":150000},{"year":2021,"income":70000},{"year":2022,"income":180000},{"year":2024,"income":240000},{"year":2025,"income":180000}],"firms":["MEHLMAN CONSULTING, INC."],"lobbyists":["BRUCE MEHLMAN","DAVID CASTAGNETTI","DEAN ROSEN","DAVID THOMAS","ELISE FINLEY PICKERING","CHARLES WOOTERS","SOHINI GUPTA","SAGE EASTMAN","STEVE HARO","LAUREN ARONSON","MICHAEL ROBINSON","MICHAEL COLLINS","CONSTANTINE HINGSON","HELEN TOLAR","NICHOLE DISTEFANO","MCKENZIE BRICE","PAUL THORNELL","STEPHEN COTE","ALEXANDER PERKINS","VICTORIA FLOOD","ROSEMARY GUTIERREZ","ZACHARY MALLOVE","CAITLIN VAN SANT","LISA GOLDMAN","ALYENE MLINAR","ERICA CHABOT","ANNIE WOLF","NAVEEN PARMAR","JON ADAME","JOSEPH BROWN","EARL FLOOD"],"issues":["MMM","HCR","BUD","VET","CPT"],"sampleDescriptions":["Quality payments for providers; clinical laboratory reimbursement; physician payment policies; chronic healthcare.\nH.R. 6 - SUPPORT for Patients and Communities Act.\nS. 3120 - HEAL Act of 2018.","General healthcare; health reform implementation; healthcare value and quality; health information technology, clinical trials, telehealth.\nPrecision Medicine Act of 2016.\nPromoting biomedical research.\nH.R. 6 - Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act.\nS. 3120 - Helping to End Addiction and Lessen (HEAL) Substance Use Disorders Act of 2018.\nS. 2680 - Opioid Crisis Response Act of 2018.","Fiscal Year 2018 Labor and Health and Human Services Appropriations.","Fiscal Year 2019 Labor and Health and Human Services Appropriations.","General healthcare; health reform; healthcare value and quality;  health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability.\nPromoting biomedical research.\nOpioid addiction and treatment.\nInternational reimbursement issues.","General healthcare; health reform; healthcare value and quality;  health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability.\nPromoting biomedical research.\nOpioid addiction and treatment.\nS. 1895: Lower Health Care Costs Act.\nPatent issues impacting clinical laboratory innovation.","General healthcare; health reform; healthcare value and quality;  health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability.\nPromoting biomedical research.\nOpioid addiction and treatment.\nInternational reimbursement issues.\nRural health.","Reimbursement issues.","General healthcare; health reform; healthcare value and quality;  health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability.\nPromoting biomedical research.\nOpioid addiction and treatment.\nRural health.","General healthcare; health reform; healthcare value and quality;  health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability.\nPromoting biomedical research.\nOpioid addiction and treatment.\nS. 1895: Lower Health Care Costs Act.\nPatent issues impacting clinical laboratory innovation.\nH.R. 1865 - Further Consolidated Appropriations Act, 2020","Reimbursement issues.\n\nMeetings with Members of Congress regarding Mayos role in supporting VAs efforts to modernize agreements with community providers of care to veterans.","General healthcare; health reform; healthcare value and quality;  health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability.\nPromoting biomedical research.\nOpioid addiction and treatment.\nS. 1895: Lower Health Care Costs Act.\nPatent issues impacting clinical laboratory innovation.\nClinical laboratory capacity and reimbursement issues.\nFinancial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, access to PPE and other materials and equipment related to the treatment of patients with COVID-19.\nH.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act - Public Law No: 116-136\nH.R. 266, Paycheck Protection Program and Health Care Enhancement Act Implementation.\nH.R. 6800, HEROES Act.","General healthcare; health reform; healthcare value and quality;  health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability.\nPromoting biomedical research.\nOpioid addiction and treatment.\nRural health.\nClinical laboratory capacity and reimbursement issues.\nFinancial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, access to PPE and other materials and equipment related to the treatment of patients with COVID-19.","General healthcare; health reform; healthcare value and quality;  health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability.\nPromoting biomedical research.\nClinical laboratory capacity and reimbursement issues.\nFinancial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, access to PPE and other materials and equipment related to the treatment of patients with COVID-19.\nH.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act - Public Law No: 116-136\nH.R. 266, Paycheck Protection Program and Health Care Enhancement Act Implementation.\nH.R. 6800, HEROES Act.\nS. 178, HEALS Act.","General healthcare; health reform; healthcare value and quality;  health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability.\nPromoting biomedical research.\nRural health.\nClinical laboratory capacity and reimbursement issues.\nFinancial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, access to PPE and other materials and equipment related to the treatment of patients with COVID-19.\nS. 178, HEALS Act.","General healthcare; health reform; healthcare value and quality;  health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability.\nPromoting biomedical research.\nClinical laboratory capacity and reimbursement issues.\nFinancial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, access to PPE and other materials and equipment related to the treatment of patients with COVID-19.\nIssues related to COVID vaccine distribution.","General healthcare; health reform; healthcare value and quality;  health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability.\nPromoting biomedical research.\nRural health.\nClinical laboratory capacity and reimbursement issues.\nFinancial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, access to PPE and other materials and equipment related to the treatment of patients with COVID-19.\nH.R. 133 - Consolidated Appropriations Act, 2021.","General healthcare; health reform; healthcare value and quality; health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability.\nPromoting biomedical research.\nClinical laboratory capacity and reimbursement issues.\nFinancial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, access to PPE and other materials and equipment related to the treatment of patients with COVID-19.\nIssues related to COVID vaccine distribution.","General healthcare; health reform; healthcare value and quality; health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability.\nPromoting biomedical research.\nRural health.\nClinical laboratory capacity and reimbursement issues.\nFinancial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, access to PPE and other materials and equipment related to the treatment of patients with COVID-19.","General healthcare; health reform; healthcare value and quality; health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability.\nPromoting biomedical research.\nClinical laboratory capacity and reimbursement issues.\nFinancial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, access to PPE and other materials and equipment related to the treatment of patients with COVID-19.\nIssues related to COVID vaccine distribution.\n\"Hospitals at Home\"; Telehealth\nH.R. 5376 - Build Back Better Act."],"years":[2018,2019,2020,2021,2022,2024,2025]}